GSK5926371 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study includes Phase 1 and Phase 2 to evaluate the safety, tolerability, and preliminary effectiveness of GSK5926371 in adults with relapsed or refractory B-NHL. Participants must have measurable disease and have received at least two prior systemic therapies, including an anti-CD20-containing regimen. The study will also characterize how the drug is processed in the body (pharmacokinetics) and observe any clinical responses. Sites are in Iowa City, NY, and Canton. The sponsor is GlaxoSmithKline.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Has histologically confirmed Relapsed/Refractory (R/R) B-NHL, for which systemic treatment is indicated,

  1. Has measurable disease,
  2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication;
  3. Has documented disease relapse, progression or disease refractory to the most recent line of therapy, per Lugano criteria.:
* Willing to use adequate contraception (Participant of childbearing potential \[POCBP\] only).
* Is capable of giving signed informed consent
* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
* Has adequate organ function.

Exclusion Criteria:

* Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.
* Has had any major surgery within 4 weeks prior to the first dose of GSK5926371 or has not recovered from prior surgeries or complications.
* Has a history of Progressive multifocal leukoencephalopathy (PML), current central nervous system (CNS) involvement by lymphoma, or a history of significant CNS disease such as uncontrolled seizures, stroke, epilepsy, CNS vasculitis, and neurodegenerative conditions.
* Has an active uncontrolled infection.
* Has received a prior Allogeneic stem cell transplant (allo-SCT) within 12 months prior to the first dose of GSK5926371 or has active graft-versus-host disease requiring systemic immunosuppressive therapy.
* Has received a prior autologous stem cell transplant within 100 days prior to the first dose of GSK5926371.
* Has received prior treatment with Chimeric antigen receptor T-cell (CAR-T) therapy within 12 weeks of first GSK5926371 administration.
* Has received prior treatment with CD19- or CD20-targeting Bispecific antibody (BsAbs) within 8 weeks of the first dose of study intervention.
* Has QT interval corrected (QTc) \>450 milliseconds (msec) or QTc \>480 msec for participants with bundle branch block.
* Has significant cardiovascular disease such as uncontrolled arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, ejection fraction \<=45% by any methods in the 12 months of enrollment, unstable angina or acute coronary syndrome including myocardial infarction within 6 months of enrollment.

Where it's running

• GSK Investigational Site
  Iowa City, Iowa, United States Recruiting
• GSK Investigational Site
  New York, New York, United States Recruiting
• GSK Investigational Site
  Canton, Ohio, United States Recruiting
• GSK Investigational Site
  Heidelberg, Victoria, Australia Recruiting
• GSK Investigational Site
  Toronto, Ontario, Canada Recruiting
• GSK Investigational Site
  Helsinki, Finland Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JMBI-001 in MYC-Positive Advanced Cancers

  This study tests JMBI-001 to see if it is safe and tolerable for adults with MYC-positive advanced cancers.

  Recruiting Phase 1/2 Chengdu Anticancer Bioscience, Ltd. · Beijing, Beijing Municipality · NCT07864701

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Toxin exposure and immune factors in B-cell non-Hodgkin lymphoma

  This study tests how toxin exposure, genetics, and immune issues relate to B-cell non-Hodgkin lymphoma in active-duty service members and other Military Health System beneficiaries.

  Recruiting Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland and 2 other locations · NCT07652580

• AI tool to spot and reduce missed doses of oral medicines for Non-Hodgkin lymphoma patients

  This project will try an AI-based system to detect early risks of not taking prescribed oral treatments and alert clinicians for adults with Non-Hodgkin lymphoma treated at Grand Hôpital de Charleroi.

  Recruiting Grand Hôpital de Charleroi · Charleroi, Hainaut · NCT07546188

• MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma

  This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.

  Recruiting at 54 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 53 other locations · NCT07519772

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.